Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KTTA |
---|---|---|
02:45 ET | 511 | 7.25 |
03:00 ET | 500 | 7.25 |
03:57 ET | 100 | 7.2503 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Pasithea Therapeutics Corp | 7.4M | -0.6x | --- |
Manuka Inc | 7.6M | -3.9x | --- |
Trevena Inc | 8.4M | -0.2x | --- |
Longeveron Inc | 7.8M | -0.3x | --- |
Theralink Technologies Inc | 6.2M | -0.4x | --- |
Vaccinex Inc | 8.7M | -0.1x | --- |
Pasithea Therapeutics Corp. is a biotechnology company. The Company is primarily focused on the discovery, research and development of treatments for Central Nervous System (CNS) disorders and RASopathies. The Company operates through two segments: Therapeutics and Clinics. Its Therapeutics segment performs activities related to the discovery, research, and development of treatments for CNS disorders and other diseases. Its Clinics segment provides business support services to anti-depression clinics in the United Kingdom and in the United States. Its therapeutic pipeline consists of four programs. Its lead product candidate, PAS-004, is a macrocyclic mitogen-activated protein kinase (MEK) inhibitor for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and Noonan syndrome, as well as lamin A/C (LMNA) cardiomyopathy and a number of oncology indications. Its other three programs are in the discovery stage.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.4M |
---|---|
Revenue (TTM) | $240.7K |
Shares Outstanding | 1.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-12.41 |
Book Value | $32.64 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 30.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -7,032.70% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.